NanoTherm® Patient Case Reports

Patient case report on the use of the NanoTherm® therapy for the treatment of recurrent glioblastoma

Course of disease in a 24-year-old patient

  • Primary tumor diagnosis of glioblastoma on June 21, 2006, WHO Grade IV, frontal left
  • Resection on July 27, 2006
  • Radiotherapy from August 30 – October 1, 2006
  • Diagnosis of relapse on November 16, 2006

DIAGNOSIS

On July 21, 2006 a histologically verified left glioblastoma, WHO Grade IV, was diagnosed in a 24-year-old patient. On July 27, 2006 the tumor measuring 5.5 cm x 5 cm was totally resected. From August 30 – October 1, 2006 radiotherapy (2 Gy/d) was performed with a total dose of 50 Gy. However, on November 16, 2006, a relapse with a tumor volume of 5.3 ml was diagnosed via MRI.

Fighting Cancer with Nanomedicine

NanoTherm® Therapy

Decision for NanoTherm® Therapy
After postoperative FET-PET and CT on January 24, 2007, the decision was made to treat with NanoTherm® therapy in combination with simultaneous radiotherapy. Prior to the instillation of the nanoparticles on January 30, 2007 an MRI was conducted in order to localize the tumor.

NanoTherm® Nanoparticles 

NanoPlan® Temperature Simulation Software  

NanoActivator® Magnetic Field Applicator

THERAPY

  • Instillation of 3.7 ml NanoTherm® in 5 depots on January 31, 2007
  • Preoperative MRI (January 30, 2007) and postoperative CT (February 5, 2007) were performed for the simulation of temperature distribution in the different tumor regions using a specific software
  • Treatment of patient with alternating magnetic field in the NanoActivator®  (February 7 - February 23, 2007: twice a week 1 hour over a period of 3 weeks, in total 6 sessions)
  • Treatment with 2 Gy for 10 days (February 7 - February 27, 2007) and 2.5 Gy for 4 days (total dose 30 Gy) concomitant to the 3-weeks NanoTherm® therapy

Side Effects

During this therapy, the patient appeared twice to feel disoriented for a few minutes. Apart from this, the patient did not complain of any further side effects.

Results

  • The follow-up CT scans showed no indication of tumor relapse at 3, 4, 8, 12, 16, 19 and 26 months after the end of the therapy
  • Last contact: January 2011, the patient is alive (47 months)

NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide certification (CE mark) as medical devices for the treatment of brain tumors. NanoTherm® therapy is currently available to national and foreign patients in dedicated hospitals in Germany.

For more information, please contact our Patient Services under T: +49 30 - 30 83 80 – 73 (free call within Germany: 0800 – 66 46 46 1) or ask your physician. You can also write us at
.

Patient case report on the use of NanoTherm® therapy for the treatment of progressive glioblastoma

Course of disease in a 47-year-old patient

  • Initial diagnosis of a left temporo-occipital glioblastoma on August 17, 2007
  • Despite radiotherapy, concomitant administration of Temozolomide as well as additional chemotherapy, clear tumor progression occurred

DIAGNOSIS

On August 17, 2007, a left temporo-occipital glioblastoma was diagnosed in a 47-year-old patient and confirmed on August 24, 2007 by a stereotactically sampled biopsy. Despite the adjacent radiotherapy (1.8 Gy/d; total dose 59 Gy) with concomitant administration of Temozolomide (from September 10 – October 26, 2007) followed by three cycles of Temozolomide (November 30 – February 5, 2008) the tumor clearly continued to grow.

Fighting Cancer with Nanomedicine

NanoTherm® Therapy

Decision for NanoTherm® Therapy
The tumor volume was 23.7 ml on February 19, 2008, and it was decided to treat the patient with a nanoparticle-mediated thermotherapy simultaneously with radiotherapy.

NanoTherm® Nanoparticles

NanoPlan® Temperature Simulation Software

NanoActivator® Magnetic Field Applicator

THERAPY

  • Instillation of 4.7 ml of NanoTherm® on March 12, 2008
  • Postoperative CT on March 13, 2008
  • Treatment of patient with alternating magnetic field in the NanoActivator® (March 18 - April 4, 2008: twice a week for 1 hour over a period of 3 weeks, 6 sessions in total)

SIDE EFFECTS

During the NanoTherm® therapy the patient did not complain of any side effects.

RESULTS

  • CT follow-up scans were performed at 3, 6, 8, 11, and 15 months following completion of the NanoTherm® Therapy
  • No tumor progression could be diagnosed
  • After 18 months, the status of the patient deteriorated rapidly
  • The patient passed in September 2009 due to tumor progression (18 months)

NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide certification (CE mark) as medical devices for the treatment of brain tumors. NanoTherm® therapy is currently available to national and foreign patients in dedicated hospitals in Germany.


For more information, please contact our Patient Services under T: +49 30 - 30 83 80 – 73 (free call within Germany: 0800 – 66 46 46 1) or ask your physician. You can also write us at .

Patient case report on the use of the NanoTherm® therapy for the treatment of relapsed glioblastoma after resection

Course of disease in a 39-year-old patient

  • Initial diagnosis of a glioblastoma on January 5, 2007, WHO Grade IV, temporal right
  • Total resection on January 8, 2007 followed by Temozolomide treatment and radiotherapy from January 30 – March 15, 2007
  • Diagnosis of a relapse on May 18, 2007

DIAGNOSIS

On January 5, 2007 a histologically confirmed glioblastoma, WHO Grade IV, temporo-occipital right, was diagnosed in the 39-year-old patient. On January 8, 2007, the tumor was completely resected. Treatment with Temozolomide was started on January 17, 2007, with a concomitant radiotherapy with a total of 59.4 Gy (1.8 Gy/d) from January 30 – March 15, 2007. From April 25 – May 16, 2007, the patient was treated exclusively with Temozolomide.

Fighting Cancer with Nanomedicine

NanoTherm® Therapy

Decision for NanoTherm® Therapy
On May 18, 2007 a relapse with a tumor volume of 2.5 ml was diagnosed by CT scan on the temporo-occipital right within the former tumor resection area. The treating neurosurgeons did not recommend resection of the relapse because of a possible hemiparesis, and instead decided to treat with NanoTherm® therapy.

NanoTherm® Nanoparticles

NanoPlan® Temperature Simulation Software

NanoActivator® Magnetic Field Applicator

THERAPY

  • Intervention with 5 punctures on July 11, 2007
  • Treatment of patient with alternating magnetic field in the NanoActivator® (July 18 - August 3, 2007: twice a week for 1 hour over a period of 3 weeks, in total 6 sessions)
  • Simultaneous radiotherapy with a total does of 29.9 Gy (13 x 2.3 Gy)

SIDE EFFECTS

The only reported side effect from the NanoTherm® therapy was sweating. No other side effects or complaints were reported by the patient.

RESULTS

  • CT follow-up scans performed at 2, 4, 7, 10, 14, 18, 22 and 24 months after completion of NanoTherm® Therapy showed no indication of a tumor relapse
  • Last contact: June 2011, the patient is alive (47 months)

NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide certification (CE mark) as medical devices for the treatment of brain tumors. NanoTherm® therapy is currently available to national and foreign patients in dedicated hospitals in Germany.


For more information, please contact our Patient Services under T: +49 30 - 30 83 80 – 73 (free call within Germany: 0800 – 66 46 46 1) or ask your physician. You can also write us at .

Contact Us

Toll free numbers:

+800-MAGFORCE (+800-62 43 67 23)

(Austria, Czech Republic, France, Germany, Italy, Poland, Spain, Switzerland, Turkey, and UK)


or  +1-844-833-9623

(United States, Canada, Guam, Puerto Rico, and US Virgin Islands)


or direct dial for English support:        

+49 30 – 30 83 80 – 73


You can also send us an email at